Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sequenom, a provider of genetic-analysis solutions, has acquired exclusive worldwide rights, excluding Hong Kong, to digital PCR and other noninvasive prenatal diagnostic intellectual property from The Chinese University of Hong Kong.
Subscribe to our email newsletter
Sequenom said that these newly acquired rights expand the company’s existing, broad intellectual property (IP) portfolio of noninvasive prenatal diagnostic methods using fetal nucleic acids obtained from a maternal sample. Financial terms were not disclosed.
According to Sequenom, the exclusive, technology-independent, digital PCR rights, which were developed and validated on the company’s MassARRAY platform and Fluidigm’s platform, can be adapted for any of the digital PCR platforms that are available, and include the use of fetal nucleic acids obtained from a maternal sample, along with methods of analysis for noninvasive Down (trisomy 21), Edward (trisomy 18), Patau (trisomy 13) and other chromosomal aneuploidy syndrome diagnoses or other autosomal recessive disorders utilizing digital PCR.
Harry Stylli, Sequenom’s president and CEO, said: “This intellectual property is platform-independent and provides Sequenom exclusivity for development and commercialization of noninvasive prenatal tests on any platform.”